Soren Aandahl of Blue Orca Capital stops by Zer0es TV to present his short thesis on Insulet Corporation (NASDAQ: PODD). Blue Orca is short Insulet $PODD and long its upstart Korean competitor EOFlow because, undisclosed to investors, last week the Federal Court of Appeals killed a preliminary injunction that protected Insulet’s key monopoly against competition from EOFlow. Blue Orca believes that this appellate court decision instantly restores EOFlow’s business from court-induced purgatory, clears the path for Medtronic $MDT (or another industry heavyweight) to acquire EOFlow and shatters Insulet’s critical monopoly on tubeless automated insulin delivery systems.